{"organizations": [], "uuid": "70e1f6df19a5d410cce0a40b61d36a86eb368f91", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-theravance-biopharma-ireland-enter/brief-theravance-biopharma-ireland-enters-global-collaboration-with-janssen-idUSB8N1J4032", "country": "US", "domain_rank": 408, "title": "BRIEF-Theravance Biopharma Ireland Enters Global Collaboration With Janssen", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-07T17:00:00.000+02:00", "replies_count": 0, "uuid": "70e1f6df19a5d410cce0a40b61d36a86eb368f91"}, "author": "", "url": "https://www.reuters.com/article/brief-theravance-biopharma-ireland-enter/brief-theravance-biopharma-ireland-enters-global-collaboration-with-janssen-idUSB8N1J4032", "ord_in_thread": 0, "title": "BRIEF-Theravance Biopharma Ireland Enters Global Collaboration With Janssen", "locations": [], "entities": {"persons": [{"name": "janssen r", "sentiment": "negative"}, {"name": "janssen", "sentiment": "negative"}, {"name": "crohn", "sentiment": "none"}], "locations": [{"name": "biopharma ireland", "sentiment": "none"}, {"name": "ireland", "sentiment": "none"}, {"name": "theravance biopharma ireland", "sentiment": "none"}], "organizations": [{"name": "crohn", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 00 PM / in 15 minutes BRIEF-Theravance Biopharma Ireland Enters Global Collaboration With Janssen Reuters Staff \nFeb 7 (Reuters) - Theravance Biopharma Ireland Limited: \n* THERAVANCE BIOPHARMA IRELAND LTD - ENTERS GLOBAL COLLABORATION WITH JANSSEN FOR TD-1473 IN INFLAMMATORY INTESTINAL DISEASES \n* THERAVANCE BIOPHARMA - ELIGIBLE FOR UP TO $1 BILLION POTENTIAL PAYMENTS, INCLUDING $100 MILLION UPFRONT \n* THERAVANCE BIOPHARMA - PHASE 2B/3 STUDY IN ULCERATIVE COLITIS, PHASE 2 STUDY IN CROHN’S DISEASE TO BEGIN IN 2018 WITH TD-1473 \n* THERAVANCE BIOPHARMA - WILL LEAD DEVELOPMENT OF TD-1473 IN ULCERATIVE COLITIS THROUGH COMPLETION OF PHASE 2B/3 PROGRAM \n* THERAVANCE BIOPHARMA - AFTER PHASE 2 CROHN’S STUDY, PHASE 2B INDUCTION PORTION OF ULCERATIVE COLITIS STUDY, JANSSEN CAN ENTER EXCLUSIVE LICENSE DEAL \n* THERAVANCE BIOPHARMA - AFTER PHASE 2, JANSSEN WOULD LEAD SUBSEQUENT DEVELOPMENT OF TD-1473 IN CROHN’S DISEASE \n* THERAVANCE BIOPHARMA - JANSSEN CAN ENTER EXCLUSIVE LICENSE DEAL FOR TD-1473 BY PAYING CO $200 MILLION FEE \n* THERAVANCE BIOPHARMA - IF TD-1473 COMMERCIALIZED, CO HAS OPTION TO CO-COMMERCIALIZE IN THE U.S. \n* THERAVANCE BIOPHARMA - IF TD-1473 COMMERCIALIZED, JANSSEN WOULD HAVE SOLE COMMERCIALIZATION RESPONSIBILITIES OUTSIDE U.S. \n* THERAVANCE BIOPHARMA - IF TD-1473 COMMERCIALIZED, CO ELIGIBLE FOR UP TO ADDITIONAL $700 MILLION DEVELOPMENT, COMMERCIALIZATION MILESTONE PAYMENTS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-07T17:00:00.000+02:00", "crawled": "2018-02-07T17:17:50.005+02:00", "highlightTitle": ""}